Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 60,718

Document Document Title
WO/2018/068357A1
Disclosed are a compound as shown in formula I, or a pharmaceutically acceptable salt, a crystal form, a solvate thereof, wherein Z is selected from (II), (III), (IV) or (V); R1 is selected from H or (VI); R2 is selected from (VII) or (V...  
WO/2018/071317A1
In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1,Q, and R5 are as defined ...  
WO/2018/071343A1
Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventi...  
WO/2018/071526A1
This disclosure is directed to agonists of the apelin receptor (APJ) with heterocyclic cores and uses of such agonists.  
WO/2018/069732A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compo...  
WO/2018/071348A1
A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can b...  
WO/2018/069470A1
The present invention relates to new profluorophores and conjugates thereof and their use for the detection of target molecule in a sample, in particular nucleic acid target molecules. The invention relates to new profluorophores and new...  
WO/2018/068739A1
The present invention relates to alkynyl heterocyclic compounds having inhibitory effects on the protein kinase activity, and to the preparation and use thereof. In particular, disclosed are alkynyl heterocyclic compounds as shown in for...  
WO/2018/068282A1
Provided are compounds of formula (I),wherein R 1, Y, X 1, X 2, R 2, R 3, R 4, R 5, R 6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment o...  
WO/2018/071622A1
The present invention provides compounds of Formula (I) wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.  
WO/2018/069863A1
A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Du...  
WO/2018/071315A2
In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1,Q, and R5 are as defined herein. The novel compou...  
WO/2018/068283A1
Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the...  
WO/2018/070502A1
There has been a demand for the development of a novel pesticide for agricultural and horticultural use for reasons such that pests still cause extensive damage on the production of agricultural and horticultural crops and the like and p...  
WO/2018/071606A1
The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which bin...  
WO/2018/068297A1
Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds,...  
WO/2018/064890A1
The invention discloses a N-acylalkyl benzamide compound with insecticidal activity and use thereof, and a derivative of the N-acylalkyl benzamide compound of general formula I. Aiming at the deficiencies of the existing N-acylalkyl benz...  
WO/2018/068017A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1...  
WO/2018/066812A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure can provide an organic electrolumine...  
WO/2018/065962A1
The invention discloses compounds of Formula (I), wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their produc...  
WO/2018/065924A1
The present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation. The present invention also relates to process for the...  
WO/2018/065607A1
The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein related peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relate...  
WO/2018/065182A1
The present invention relates to compounds (I) wherein the variables are defined as given in the description and claims. The invention further relates to uses, processes and intermediates for compounds (I).  
WO/2018/067615A1
The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are i...  
WO/2018/067834A1
Relapse and resistance to therapy is the most significant challenge in the treatment of lymphoblastic leukemia. Mutations in NT5C2 (a cytosolic nucleotidase activated by gain of function mutations in about 20% of relapse ALL cases) chara...  
WO/2018/067860A1
This disclosure relates to salt forms of compounds capable of activating PPAR╬┤ for use in drug substance and drug product development, and related compositions and methods.  
WO/2018/065768A1
The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having u...  
WO/2018/065921A1
The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, ...  
WO/2018/065953A1
The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challe...  
WO/2018/065311A1
The present invention provides a composition comprising (A) a compound of formula (I): (I) wherein R is methyl or methoxy, R is hydrogen, methyl or ethoxy and A is a substituted heteroaryl group, or an N-oxide or salt form thereof, and (...  
WO/2018/064632A1
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...  
WO/2018/060714A1
The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following gene...  
WO/2018/064589A1
The present application provides bifunctional compounds of Formula I or II: or an enantiomer, diastereomer, or stereoisomer, or a pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties. The present a...  
WO/2018/060742A1
The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30)...  
WO/2018/059279A1
Disclosed is a method for synthesizing a novel chiral ligand, a metal chelate, a variety of non-natural amino acids, Maraviroc and a key intermediate thereof. In the invention, (R)-2-methyl proline is selected and used as a starting raw ...  
WO/2018/059549A1
Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, ...  
WO/2018/060174A1
The invention relates to substituted benzimidazoles of formula (I), to the use thereof for treating and/or preventing diseases, and to the use thereof for producing drugs for treating and/or preventing diseases, in particular for treatin...  
WO/2018/064092A1
Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors...  
WO/2018/060689A1
The present invention relates to substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having ut...  
WO/2018/060091A1
The present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions and mixtures comprising these compounds, and to the use thereof as biologically active compoun...  
WO/2018/060691A1
The present invention relates to a class of cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30...  
WO/2018/059455A1
Provided in the present invention are a 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative having the structure shown below in formula (I) and a pharmaceutical composition and use thereof. The 1-[(pyridin-3-yl-sulfonyl)-1h...  
WO/2018/062924A1
The present disclosure relates to a novel tetrahydropyridine derivative compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, methods for preparing the compounds, methods for inhibiting UDP-3-O-(R-3-hydroxymyri...  
WO/2018/062811A1
The present invention relates to a composition for formaldehyde detection or concentration measurement, and to two-photon rate-based fluorescence imaging and concentration quantification of formaldehyde in a cell or tissue using the comp...  
WO/2018/060843A1
The present invention is directed to methods for producing crystals or aggregates of organic compounds using a composition comprising a surfactant-water mixture, the organic compound and optionally an organic solvent as starting composit...  
WO/2018/055402A1
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...  
WO/2018/054721A1
The present invention relates to compounds of formula I wherein the variables are defined as given in the description and claims. The invention further relates to uses and composition for compounds of formula I.  
WO/2018/058098A1
The present invention provides methods for treating Alzheimer's Disease, or preventing synaptic death associated with Alzheimer's Disease by administering a Pyk2 inhibitor. In certain embodiments, the Pyk2 inhibitor is specific for Pyk2....  
WO/2018/057810A1
The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein. The compounds of formula I se...  
WO/2018/054711A1
The present invention relates to compounds of formula I wherein the variables are defined as given in the description and claims. The invention further relates to uses and composition for compounds of formula I.  

Matches 1 - 50 out of 60,718